Request Demo
Last update 25 May 2026
Albenatide
Last update 25 May 2026
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms PC-DAC:Exendin-4, PCDAC, 阿贝那肽 + [4] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 3958
Source: *****
Sequence Code 37437
Source: *****
Related
13
Clinical Trials associated with AlbenatideNCT05990374
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
CTR20222496
评价健康受试者皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林药物-药物相互作用的临床研究
[Translation] Clinical study to evaluate the drug-drug interactions of subcutaneous CJC-1134-PC injection with metformin, atorvastatin, and warfarin in healthy subjects
NCT07057271
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
100 Clinical Results associated with Albenatide
Login to view more data
100 Translational Medicine associated with Albenatide
Login to view more data
100 Patents (Medical) associated with Albenatide
Login to view more data
2
Literatures (Medical) associated with Albenatide01 Apr 2010Current diabetes reportsQ2 · MEDICINE
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Q2 · MEDICINE
Review
Author: Christensen, Mikkel ; Knop, Filip K.
Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.
01 Apr 2008GastroenterologyQ1 · MEDICINE
An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis
Q1 · MEDICINE
Article
Author: Daniel J. Drucker ; Laurie L. Baggio ; Xiemin Cao ; Qingling Huang
BACKGROUND & AIMS:
Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis through multiple mechanisms including direct actions on the endocrine pancreas and indirect activation of central nervous system circuits regulating gastric emptying, satiety, and body weight. Because native GLP-1 is rapidly degraded, there is considerable interest in development of more potent GLP-1 receptor (GLP-1R) agonists with sustained activity; however, the extent to which much larger GLP-1R agonists will mimic some or all of the actions of smaller peptides remains uncertain.
METHODS:
We studied the actions of CJC-1134-PC, a recombinant human serum albumin-exendin-4 conjugated protein, at the GLP-1R using heterologous cells expressing the GLP-1R in vitro and both wild-type and Glp1r(-/-) mice in vivo.
RESULTS:
CJC-1134-PC activated GLP-1R-dependent signaling in baby hamster kidney-GLP-1R cells and acutely lowered blood glucose in wild-type but not in Glp1r(-/-) mice. Moreover, acute administration of CJC-1134-PC rapidly activated c-Fos expression in multiple regions of the central nervous system, acutely inhibited gastric emptying, and produced sustained inhibition of food intake in a GLP-1R-dependent manner. Furthermore, chronic daily treatment of high-fat diet-fed wild-type mice with CJC-1134-PC for 4 weeks led to improved glucose tolerance, increased levels of glucose-stimulated insulin, decreased HbA1c, and weight loss associated with decreased hepatic triglyceride content.
CONCLUSIONS:
These findings illustrate that a high-molecular-weight exendin-4-albumin conjugate retains the ability to mimic a full spectrum of GLP-1R-dependent actions, including activation of central nervous system circuits regulating gastric emptying, food intake, and body weight.
100 Deals associated with Albenatide
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | NDA/BLA | China | 25 Apr 2024 | |
| Obesity | Phase 1 | China | 25 May 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 73 | (Arm 1 - Weekly CJC-1134-PC) | wvlfkfcshz(jbflfeysic) = mllrbrzonf awkqrxsypa (hxzcwuudzr, 0.597) View more | - | 19 Jul 2017 | ||
(Arm 2 - Weekly CJC-1134-PC) | wvlfkfcshz(jbflfeysic) = tidltkkuap awkqrxsypa (hxzcwuudzr, 0.627) View more | ||||||
Phase 2 | 122 | (1.5 mg CJC-1134-PC) | pqkwjcepon(julzlyuszg) = vupfsimdcr snrjdfptum (wockazhshv, 0.883) View more | - | 02 Jun 2017 | ||
(1.5 or 2.0 mg CJC-1134-PC) | pqkwjcepon(julzlyuszg) = hmysiwnwpb snrjdfptum (wockazhshv, 0.827) View more | ||||||
Phase 2 | 90 | (1.5 mg CJC-1134-PC) | qoslocjmak(nyqamlqymk) = bhfjcsgdbp wjyrvnzfes (aywjhsnsbk, 1.226) View more | - | 02 Jun 2017 | ||
(1.5 mg or 2.0 mg CJC-1134-PC) | qoslocjmak(nyqamlqymk) = zhnyepzzvb wjyrvnzfes (aywjhsnsbk, 0.672) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free